Abstracts tagged "systemic lupus erythematosus (SLE) and treatment"

Abstract Number: 1409 • 2012 ACR/ARHP Annual Meeting
A Multicentre Clinical Study of Umbilical Cord Mesenchymal Stem Cells Transplantation in Active Systemic Lupus Erythematosus
Lingyun Sun¹, Dandan Wang¹, Jing Li², Miao Zhang³, Yu Zhang⁴ and Xia Li¹, ¹Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China, ³Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, China, ⁴Department of Rheumatology, Subei People's Hospital of Jiangsu Province, Yangzhou, China
Background/Purpose: Umbilical cord (UC) derived mesenchymal stem cells (MSCs) have shown safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE) in…
Abstract Number: 631 • 2012 ACR/ARHP Annual Meeting
Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
Simone Fargetti¹, Samuel K. Shinjo², Sandra G. Pasoto¹, Ana L. Calich¹, Eloisa Bonfa³ and Eduardo F. Borba¹, ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that…
Abstract Number: 635 • 2012 ACR/ARHP Annual Meeting
Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Leslie Harris¹, Ratnesh Chopra¹, Ann K. Rosenthal² and Mary E. Cronin³, ¹Division of Rheumatology/Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus ( SLE) is characterized by the formation of autoantibodies, and over-exuberant antigen presentation may account for some of this pathology .…
Abstract Number: 641 • 2012 ACR/ARHP Annual Meeting
Study of Anti-Müllerian Hormone and Probability of Pregnancy in 112 Systemic Lupus Erythematosus Patients Exposed or Not to Cyclophosphamide
Nathalie Morel¹, Anne Bachelot², Zeina Chakhtoura², Zahir Amoura¹, Olivier Aumaitre³, Jean-Emmanuel Kahn⁴, Du Boutin⁵, Pierre Duhaut⁶, Dominique Farge⁷, Camille Francès¹, Lionel Galicier⁸, Gaëlle Guettrot-Imbert³, Jean-Robert Harlé⁹, Olivier Lambotte¹⁰, Véronique Le Guern¹¹, Jean-Charles Piette¹², Jacques Pourrat¹³, Karim Sacre¹⁴, Damien Sene¹⁵, Salim Trad¹⁶, Elisabeth Vidal¹⁷, Lamiae Grimaldi¹⁸, Christiane Coussieu¹⁹, Nathalie Costedoat-Chalumeau²⁰ and PLUS²¹, ¹Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²Endocrinology, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ³Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁶Internal Medicine and RECIF, CHU Nord, Amiens, France, ⁷Medicine, EBMT, Paris, France, ⁸Internal Medicine, Hopital Saint Louis, Paris, France, ⁹Internal Medicine, CHU Toulouse, Toulouse, France, ¹⁰Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, ¹¹Department of Internal Medicine, Cochin Hospital, Paris, France, ¹²Internal Medicine 2, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ¹³Toulouse University Hospital, University of Toulouse, Toulouse, France, ¹⁴Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ¹⁵Internal Medicine, Hopital Lariboisière, Paris, France, ¹⁶Internal Medicine, Hopital Ambroise Paré, Paris, France, ¹⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹⁸Société Laser, Paris, France, ¹⁹Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²⁰Internal Medicine, Hopital Cochin, Paris, France, ²¹Paris, France
Background/Purpose: Cyclophosphamide (CYC), a drug commonly used in systemic lupus erythematosus (SLE), is associated with a risk of ovarian failure resulting in infertility. In the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].